CHIPs-VTE program to prevent hospital-acquired blood clots in hospitalized patients
Official title: Effect on Thromboprophylaxis Among Hospitalized Patients Using a System-wide Multifaceted Quality Improvement Intervention: Rationale and Design for a Multicenter Cluster Randomized Clinical Trial in China
Run by China-Japan Friendship Hospital · NCT04211181 · Data updated 2026-11-12
This project tests whether a hospital-wide package of risk checks, computer alerts, staff education, and audits can increase appropriate clot-prevention for hospitalized patients in China.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years and up |
| Sex | All |
| Enrollment | 5800 (estimated) |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | August 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | September 17, 2025 |
| Trial ID | NCT04211181 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 14 or older admitted to a participating hospital with an expected stay of at least 72 hours who can give informed consent and be followed for three months.
✕Probably not a fit
Patients who already have a diagnosed VTE at or before enrollment, who require full-dose anticoagulation, have very short admissions, or cannot be followed for three months are unlikely to benefit from the intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, cluster-randomized, open-label trial that randomizes hospitals within the CURES network to a multifaceted quality improvement intervention or to usual care. Hospitals in the intervention arm implement mandatory VTE risk assessment, a computer-based clinical decision support and reminder system, strengthened staff education, and ongoing audit and feedback. Patients aged 14 or older with an expected hospital stay of at least 72 hours are enrolled at the cluster level and followed for outcomes related to hospital-acquired venous thromboembolism. The control hospitals continue existing policies or recommended care while outcomes such as appropriate prophylaxis use and VTE events are compared between arms.
Why it matters
Potential benefit: If successful, the program could increase appropriate use of VTE prevention and reduce hospital-acquired blood clots among inpatients.
How similar studies have gone: Multifaceted quality-improvement programs in other countries have increased prophylaxis rates and reduced VTE in some settings, but no single protocol has been widely proven to drive breakthrough improvements across China.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged ≥14 years 2. Have an expected hospital stay ≥72 hours for medical and/or surgical treatment 3. Written informed consent Exclusion Criteria: 1. Inability to be followed-up at until 3 months after randomization 2. Have participated in similar trials or are undergoing other clinical trials 3. Refuse or are unable to give informed consent 4. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment 5. Requiring a full dose of anticoagulant treatment (e.g., recent VTE, atrial fibrillation).
Where it's running
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Zhenguo Zhai, Doctor — China-Japan Friendship Hospital
- Study coordinator: Zhenguo Zhai, Doctor
- Email: zhaizhenguo2011@126.com
- Phone: 86-10-84206265
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prognostic value of the 2026 AHA/ACC PE classification in ED patients with acute PE
This study tests whether the 2026 AHA/ACC five-category PE classification helps predict 30-day major adverse pulmonary embolism events in adults with acute PE presenting to the ED.
-
Blood test and software to guide treatment for venous thromboembolism
This project tests whether a blood-based ctDNA test combined with a software risk score can predict if VTE will come back in adults with cancer-associated DVT or PE who have finished 3–12 months of anticoagulation.
-
Aspiration thrombectomy with the Symphony or Prodigy devices
This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.
-
Timing of anticoagulation for preventing blood clots in patients with brain hemorrhage
This study is testing whether starting blood-thinning treatment early or later can help prevent blood clots in patients with bleeding in the brain while keeping them safe from more bleeding.
-
Personalized blood thinner treatment for hip and knee replacement patients
This study is testing if personalized blood thinner treatments can better prevent blood clots and bleeding in patients getting hip or knee replacements compared to standard treatments.
-
Evaluating a new decision support tool for diagnosing blood clots
This study is testing a new tool to help doctors diagnose blood clots in patients who might have conditions like pulmonary embolism or deep vein thrombosis, using fresh blood samples.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.